Article

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest

Department of Molecular Virology, Immunology, and Medical Genetics, The Arthur G. James Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 11/2002; 110(7):983-92. DOI: 10.1172/JCI15950
Source: PubMed

ABSTRACT The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets. However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo. We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12. This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes. Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcgammaRIII) and the IL-12 receptor expressed on NK cells. Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity. These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.

0 Followers
 · 
126 Views
  • Source
    • "In vitro, this process is termed as ADCC. Laboratory studies have shown that HER2-overexpressing breast cancer cell lines are susceptible to ADCC in the presence of trastuzumab (Carson et al, 2001; Parihar et al, 2002; Gennari et al, 2004), and in vivo activity of trastuzumab has been correlated with significantly increased number of peritumoral lymphocytes and monocytes and in vitro ADCC (Gennari et al, 2004; Arnould et al, 2006). Additional studies have indicated that NK cells are keys for trastuzumab-mediated ADCC (Cooley et al, 1999; Clynes et al, 2000; Mimura et al, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In HER2-overexpressing breast cancer, accumulating preclinical evidences suggest that some chemotherapies, like trastuzumab, but also taxanes, are able to trigger a T helper 1 (Th1) anticancer immune response that contribute to treatment success. T helper 1 immune response is characterised by the expression of the transcription factor T-bet in CD4 T lymphocytes. We hypothesised that the presence of such T cells in the tumour immune infiltrates following neoadjuvant chemotherapy would predict patient survival. In a series of 102 consecutive HER2-overexpressing breast cancer patients treated by neoadjuvant chemotherapy incorporating antracyclines or taxane and trastuzumab, we studied by immunohistochemistry the peritumoral lymphoid infiltration by T-bet+ lymphocytes before and after chemotherapy in both treatment groups. Kaplan-Meier analysis and Cox modelling were used to assess relapse-free survival (RFS). Fifty-eight patients have been treated with trastuzumab-taxane and 44 patients with anthracyclines-based neoadjuvant chemotherapy. The presence of T-bet+ lymphocytes in peritumoral lymphoid structures after chemotherapy was significantly more frequent in patients treated with trastuzumab-taxane (P=0.0008). After a median follow-up of 40 months, the presence of T-bet+ lymphocytes after neoadjuvant chemotherapy confers significantly better RFS (log-rank test P=0.011) only in patients treated with trastuzumab-taxane. In this population, multivariate Cox regression model showed that only the presence of T-bet+ lymphocytes in peritumoral lymphoid structures after neoadjuvant chemotherapy was independently associated with improved RFS (P=0.04). These findings indicate that the tumour infiltration by T-bet+ Th1 lymphocytes following neoadjuvant trastuzumab-taxane may represent a new independent prognostic factor of improved outcome in HER2-overexpressing breast carcinoma.
    British Journal of Cancer 07/2011; 105(3):366-71. DOI:10.1038/bjc.2011.261 · 4.82 Impact Factor
  • Source
    • "immunity, suggesting an additional role for CD16 [18] [19]. Moreover , various in vitro studies showed that NK activated through the CD16 receptor produce TNF-a and INF-c which is potentiated when both IL-12 receptor and CD16 were mutually engaged [20] [21]. In the present study we present evidences demonstrating that cross-linking of CD16 on NK cells from human peripheral blood, up-regulates the expression of activating markers and receptors such as CD25, CD69, CD40L, NKp44, NKp30 and the intensity of CD56 expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human NK cells are classified into two populations according to the intensity of CD56 surface expression, as well as possession of CD16, FcRIII. CD56(dim)CD16(bright) make up 90% circulating NK cells, whereas CD56(bright)CD16(-/dim) comprises the remaining 10%. Here we report that peripheral NK cells upon CD16 cross-linking up-regulates the expression of activating markers and receptors such as CD25, CD69, NKp44, NKp30, CD40L and the intensity of CD56 expression. Additionally, co-culturing immature DCs with CD16 activated NK cells was found to significantly increase the expression of maturation markers on DCs. These results suggest that CD16 cross-linking on resting peripheral blood NK cells triggers the activation of these cells and induces the appearance of CD56(bright) NK cells. The latter were found capable of producing pro-inflammatory cytokines, IFN-gamma and TNF-alpha and notably IL-12.
    Cellular Immunology 01/2010; 264(1):86-92. DOI:10.1016/j.cellimm.2010.05.002 · 1.87 Impact Factor
  • Source
    • "Note that the highest antitumor activity has been found when Trastuzumab is combined with paclitaxel (Burstein , 2003), which suppresses adaptive immunity but selectively increases NK activity (Tsavaris et al., 2002). On the other hand, efforts to stimulate NK activity through specific cytokines (Parihar et al., 2002; Repka et al., 2003 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer.
    Journal of Cellular Physiology 10/2005; 205(1):10-8. DOI:10.1002/jcp.20387 · 3.87 Impact Factor
Show more

Preview

Download
0 Downloads
Available from